Slingshot members are tracking this event:

Amgen (AMGN) set for FDA action date for migraine treatment Erenumab on May 17th, 2018

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
NVS Community voting in process
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Migraine, Erenumab